Citations

Showing 10 of 108083 citations.

Anesthesia-Related Outcomes for Endovascular Stroke Revascularization
Brinjikji, Waleed , Pasternak, Jeffrey J., Murad, M. Hassan , Cloft, Harry J. , Welch, Tasha L. , Kallmes, David F. , Pasternak, Jeffrey, Murad, Mohammad H, Murad, M Hassan , Welch, Tasha L , Rabinstein, Alejandro A.

Mayo Clinic

Stroke | September 14, 2017 | Volume: 48 | Issue: 10 | Pages: 2784-2791

10.1161/strokeaha.117.017786 | PMID 28904228 Get It

Background and Purpose— There is currently controversy on the ideal anesthesia strategy during mechanical thrombectomy for acute ischemic stroke. We performed a systematic review and meta-analysis of studies comparing clinical and angiographic outcomes of patients undergoing general anesthesia (GA group) and those receiving either local anesthesia or conscious sedation (non-GA group). Methods— A literature search on anesthesia and endovascular treatment of acute ischemic stroke was performed. Using random-effects meta-analysis, we evaluated the following outcomes: recanalization rate, good functional outcome at 90 days (modified Rankin Score≤2), symptomatic intracranial hemorrhage, death, vascular complications, respiratory complications, procedure time, and time to groin puncture. Results— Twenty-two studies (3 randomized controlled trials and 19 observational studies), including 4716 patients (1819 GA and 2897 non-GA) were included. In the nonadjusted analysis, patients in the GA group had higher odds of death (odds ratio [OR], 2.02; 95% confidence interval [CI], 1.66–2.45) and respiratory complications (OR, 1.70; 95% CI, 1.22–2.37) and lower odds of good functional outcome (OR, 0.58; 95% CI, 0.48–0.64) compared with the non-GA group. There was no difference in procedure time between the 2 primary comparison groups. When adjusting for baseline National Institutes of Health Stroke Scale, GA was still associated with lower odds of good functional outcome (OR, 0.59; 95% CI, 0.29–0.94). When considering studies performed in the stent-retriever/aspiration era, there was no significant difference in good neurological outcome rates (OR, 0.84; 95% CI, 0.67–1.06). Conclusions— Acute ischemic stroke patients undergoing intra-arterial therapy may have worse outcomes when treated with GA as compared with conscious sedation/local anesthesia. However, major limitations of current evidence (ie, retrospective studies and selection bias) indicate a need for adequately powered, multicenter randomized controlled trials to answer this question.
Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience
Jin, Zhaohui , Truty, Mark J. , Smoot, Rory L. , Nagorney, David M. , Kendrick, Michael L. , Kipp, Benjamin R. , Johnson, Benny, Smoot, Rory L , Jin, Zhaohui , Johnson, Benny , Grothey, Axel

Mayo Clinic

The Oncologist | September 14, 2017 | Volume: 23 | Issue: 1 | Pages: 128-134

10.1634/theoncologist.2017-0230 | PMID 28904173 Get It

Abstract Background BRAF V600E mutations are present in 8%–10% of patients with metastatic colorectal cancer (mCRC) and portend poor prognosis. This study investigated the impact of metastasectomy for patients with BRAF V600E mCRC. Subjects, Materials, and Methods Using prospective clinical and molecular data, patients with BRAF V600E mCRC were analyzed for clinical characteristics and survival. Statistical analyses utilized the Kaplan-Meier method, log-rank test, and Cox proportional hazard models. Results Fifty-two patients were identified between July 1, 2008, and January 4, 2016. Patient characteristics included median age 65 years, 61% female, Eastern Cooperative Oncology Group performance status ≤1, 71% with right-sided tumors, and 28% with liver-limited metastasis. In the first-line setting, 7% (4/52) received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/bevacizumab (BEV) and 81% were treated with doublet chemotherapy consisting of fluoropyrimidine, oxaliplatin, and BEV. Median overall survival (OS) for all 52 patients was 25 months with median progression-free survival (PFS) of 9.3 months. With median follow-up of 18.3 months, 21 patients underwent metastasectomy with longer OS (29.1 months vs. 22.7 months, hazard ratio [HR] = 0.33; confidence interval [CI], 0.12–0.78; p = .01) and PFS (13.6 months vs. 6.2 months, HR = 0.53, CI, 0.28–0.97; p = .03) compared with the non-metastasectomy cohort. In multivariate analysis, metastasectomy remained significant for improved survival outcomes (HR = 0.52; 95% CI, 0.07–1.02; p = .02). Median disease-free survival after metastasectomy was 9.7 months (95% CI, 5.5–19.5). Two patients remain disease-free at the time of last follow-up, with one patient without relapse for greater than 2 years (28.9 months). Conclusion Multimodality therapy incorporating metastasectomy for BRAF V600E mCRC should be considered and might be associated with improved overall survival in select patients. Implications for Practice BRAF V600E metastatic colorectal cancer (mCRC) represents an extremely difficult molecular subset of colorectal cancer to treat. To date, this subset remains refractory to standard chemotherapies, prompting extensive clinical investigation regarding novel treatment approaches and targeted modalities. While the use of metastasectomy for expanded RAS wild-type and RAS mutated mCRC has resulted in improved overall survival for select patients, utilization of metastasectomy in patients with BRAF V600E mCRC remains controversial. This article explores the authors' experience with BRAF V600E mCRC to ascertain whether a multidisciplinary approach incorporating metastasectomy for well-selected patients improves overall survival.
Outcomes of Vaginal Hysterectomy With and Without Perceived Contraindications to Vaginal Surgery
Schmitt, Jennifer, Occhino, John A. , Weaver, Amy L. , McGree, Michaela E. , Gebhart, John B.

Mayo Clinic

Female Pelvic Medicine & Reconstructive Surgery | September 14, 2017 | Volume: 25 | Issue: 1 | Pages: 41-48

10.1097/spv.0000000000000469 | PMID 28914709 Get It

Objective The aim of this study was to compare outcomes of vaginal hysterectomy between patients with and without the following perceived contraindications to vaginal surgery: uterine weight greater than 280 g, prior cesarean delivery, no vaginal parity, and obesity. Methods Retrospective cohort of benign vaginal hysterectomies between 2009 and 2013 was obtained. Outcomes included uterine debulking, transfusion, intraoperative complications, length of stay, and Accordion grade 2+ postoperative complications. For each outcome, the association between the presence of each contraindication and the outcome was evaluated using univariate and multivariate logistic regression models. Results Among 692 vaginal hysterectomies, 11% (76/691) had a uterine weight greater than 280 g, 11.3% (78/690) had no vaginal parity, 14.9% (103/690) had a history of cesarean delivery, and 37.7% (248/657) had a body mass index of 30 kg/m2 or greater; 110 (15.9%) had 2 or more contraindications. Uterine debulking occurred in 146 women (21.1%), and both uterine weight greater 280 g (adjusted odds ratio, 39.2; 95% confidence interval, 18.4–83.5) and prior cesarean delivery (adjusted odds ratio, 2.1; 95% confidence interval, 1.2–3.7) were significantly associated with an increased likelihood of uterine debulking after adjusting for age, hematologic disease, and preoperative diagnosis. None of the contraindications were significantly associated with need for a blood transfusion, presence of an intraoperative complication, length of stay greater than 2 days, or presence of an Accordion grade 2+ postoperative complication, which occurred in 2.7%, 2.5%, 14.0%, and 6.9% of all women, respectively. Conclusions Vaginal hysterectomy can be safely performed with favorable outcomes, even in women with a uterus greater than 280 g, prior cesarean delivery, no vaginal parity, and obesity. Our findings challenge several perceived contraindications to vaginal hysterectomy.
Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma
Sajed, Dipti P. , Carey, Christopher D. , Severson, Eric A. , Afrogheh, Amir , Blacklow, Stephen C. , Chau, Nicole G. , Lin, Derrick T., García, Joaquín J. , Sholl, Lynette M. , Faquin, William C , Johnson, Carl A., Krane, Jeffrey F. , Jo, Vickie Y. , Aster, Jon Christopher

Mayo Clinic

American Journal of Surgical Pathology | September 14, 2017 | Volume: 41 | Issue: 11 | Pages: 1473-1482

10.1097/pas.0000000000000945 | PMID 28914715 Get It

NOTCH1 is frequently mutated in adenoid cystic carcinoma (ACC). To test the idea that immunohistochemical (IHC) staining can identify ACCs with NOTCH1 mutations, we performed IHC for activated NOTCH1 (NICD1) in 197 cases diagnosed as ACC from 173 patients. NICD1 staining was positive in 194 cases (98%) in 2 major patterns: subset positivity, which correlated with tubular/cribriform histology; and diffuse positivity, which correlated with a solid histology. To determine the relationship between NICD1 staining and NOTCH1 mutational status, targeted exome sequencing data were obtained on 14 diffusely NICD1-positive ACC specimens from 11 patients and 15 subset NICD1-positive ACC specimens from 15 patients. This revealed NOTCH1 gain-of-function mutations in 11 of 14 diffusely NICD1-positive ACC specimens, whereas all subset-positive tumors had wild-type NOTCH1 alleles. Notably, tumors with diffuse NICD1 positivity were associated with significantly worse outcomes (P=0.003). To determine whether NOTCH1 activation is unique among tumors included in the differential diagnosis with ACC, we performed NICD1 IHC on a cohort of diverse salivary gland and head and neck tumors. High fractions of each of these tumor types were positive for NICD1 in a subset of cells, particularly in basaloid squamous cell carcinomas; however, sequencing of basaloid squamous cell carcinomas failed to identify NOTCH1 mutations. These findings indicate that diffuse NICD1 positivity in ACC correlates with solid growth pattern, the presence of NOTCH1 gain-of-function mutations, and unfavorable outcome, and suggest that staining for NICD1 can be helpful in distinguishing ACC with solid growth patterns from other salivary gland and head and neck tumors.
Cancer-associated weight loss: releasing its firm grip on negative clinical outcomes
Yusuf, Naima, Jatoi, Aminah

Mayo Clinic

Current Opinion in Supportive & Palliative Care | September 13, 2017 | Volume: 11 | Issue: 4 | Pages: 259-260

10.1097/spc.0000000000000297 | PMID 28914643 Get It

In-Hospital Outcomes of Tumor Lysis Syndrome: A Population-Based Study Using the National Inpatient Sample
Durani, Urshila , Shah, Nilay D. , Go, Ronald S. , Durani, Urshila

Mayo Clinic

The Oncologist | September 13, 2017 | Volume: 22 | Issue: 12 | Pages: 1506-1509

10.1634/theoncologist.2017-0147 | PMID 28904174 Get It

Abstract The epidemiology and outcomes of tumor lysis syndrome (TLS) are understudied. We used the National Inpatient Sample (NIS), a nationally representative weighted sample of all U.S. hospital discharges, to study outcomes and predictors of mortality in hospitalized patients with TLS. The NIS was queried for patients with a discharge diagnosis of TLS (ICD-9 code 277.88) from 2010–2013. Baseline characteristics and outcomes were analyzed. A multivariable logistic regression analysis was performed to identify predictors of mortality. From 2010–2013, 28,370 patients were discharged with a diagnosis of TLS. The most common malignancies were non-Hodgkin lymphoma (30%), solid tumors (20%), acute myeloid leukemia (19%), and acute lymphocytic leukemia (13%). Overall in-hospital mortality was 21%. The median length of stay was 10 days (IQR 5-22). Sixty-nine percent of patients experienced a severe complication, including sepsis (22%, 95% confidence interval [CI] 21–23), dialysis (15%, 95% CI 14–16), acute respiratory failure (23%, 95% CI 22–24), mechanical ventilation (16%, 95% CI 15–17), gastrointestinal hemorrhage (6%, 95% CI 5–7), cerebral hemorrhage (2%, 95% CI 2–3), seizures (1%, 95% CI 0.6–1), and cardiac arrest (2%, 95% CI 2–3). Predictors of mortality were derived from a multivariable logistic regression and included age, Elixhauser comorbidity score, insurance status, teaching versus nonteaching hospital, and cancer type. Predictors of increased length of stay included age, race, teaching versus nonteaching hospital, and cancer type. In the U.S., many patients with TLS develop life-threatening complications and a quarter die during hospitalization. As more cancer treatments become available, strategies to improve the supportive care of patients with TLS should be a priority.
Efficacy of Antitoxin Therapy in Treating Patients With Foodborne Botulism: A Systematic Review and Meta-analysis of Cases, 1923–2016
O’Horo, John C. , Harper, Eugene P. , Rafei, Abdelghani El , Ali, Rashid , Sakusic, Amra , Saleh, Omar Abu , Marcelin, Jasmine R , Rao, Agam K. , Sobel, Jeremy, Tosh, Pritish K. , El Rafei, Abdelghani, Abu Saleh, Omar M, Tan, Eugene M. , Marcelin, Jasmine , O'Horo, John C , DeSimone, Daniel C.

Mayo Clinic

Clinical Infectious Diseases | September 13, 2017 | Volume: 66 | Issue: suppl_1 | Pages: S43-S56

10.1093/cid/cix815 | PMID 29293927 Get It

Detecting myocardial infarction type 2: targetting the right patients
Thygesen, Kristian , Jaffe, Allan S. , Jaffe, Allan S.

Mayo Clinic

European Heart Journal | September 13, 2017 | Volume: 38 | Issue: 47 | Pages: 3521-3522

10.1093/eurheartj/ehx557 | PMID 29029142 Get It

Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations
Jakub, James W. , Peled, Anne Warren, Gray, Richard J. , Greenup, Rachel A., Sacchini, Virgilio , McLaughlin, Sarah A. , Tchou, Julia , Vierkant, Robert A. , Jakub, James W , Vierkant, Robert A , Kiluk, John V. , Degnim, Amy C. , Willey, Shawna C.

Mayo Clinic

JAMA Surgery | September 13, 2017 | Volume: 153 | Issue: 2 | Pages: 123

10.1001/jamasurg.2017.3422 | PMID 28903167 Get It